Polyneuron CEO Ruben Herrendorff: ‘The excitement to build something that is hopefully of significance and lasting value is rewarding’ (venturelab.swiss)

Polyneuron extends Series A to CHF 36.5 million by raising an additional CHF 14 million to advance its lead product candidate (venturelab.swiss)

Polyneuron Extends Series A to CHF36.5 Million (startupticker.ch)

25 most promising scale-ups in Switzerland (venturelab.swiss)

FDA approval paves the way for two Swiss startups (startupticker.ch)

Polyneuron submits clinical trial application (startupticker.ch)

Venture Kick to inject 5 million Swiss francs in 80 projects (startupticker.ch)

TOP 100 - Meet the 5 Best Swiss Biotech Startups of 2019 Ranking (venturelab.swiss)

The next big step with experienced personalities (startupticker.ch)

Polyneuron Raises CHF22.5 M for Autoimune Diseases (startupticker.ch)

Polyneuron completes CHF3 million seed financing (startupticker.ch)

BaseLaunch selektiert sechs Startups für zweite Förderphase (startupticker.ch)

BaseLaunch startups: From gene therapies to digital measurement (startupticker.ch)

BaseLaunch startups: From gene therapies to digital measurement (startupticker.ch)

Polyneuron Pharmaceuticals receives EMA orphan drug designation (startupticker.ch)

Polyneuron Pharmaceuticals receives EMA orphan drug designation (startupticker.ch)

Biotech startups receive the CTI startup label (startupticker.ch)

Polyneuron receives a CTI (Innosuisse) grant of CHF 640'000 together with the University of Basel for the development of a new therapy for multifocal motor neuropathy.

Polyneuron obtains the orphan drug designation from the European Medicines Agency (EMA) for PN-1007 as a novel treatment for anti-MAG neuropathy.

Publication of top in vivo data with lead compound PN-1007 in renowned scientific journal "PNAS".

Award of the CTI Start-up Label.

Presentation of promising PN-1018 in vitro data at the Swiss Meeting on Muscle Research.

Initiation of PN-1007 clinical trial-enabling studies (preclinical development phase)

Winner of the Brain Forum 2016 Innovation Award (10'000 CHF)

Closing of CHF 3.1 million seed financing round.

Hiring of postdoctoral researchers with specialization in neuroimmunology and in carbohydrate chemistry (currently 6 employees and 3 master students).

Approval of grant by the Swiss Foundation for Research on Muscle Diseases (CHF 238'500).

Promising data in animal model for anti-MAG neuropathy.

Approval of grant by the Gebert Rüf Foundation (CHF 390'000).

Winner of the IMD startup competition 2016.

Antibody-Catch™ platform patent filed.

Handelszeitung article.

Approval of grant by the Neuromuscular Research Association Basel (CHF 50'000).

Winner of Venture Kick Phase III (CHF 130'000).

Start of CTI-funded collaboration between Polyneuron and University of Basel (CHF 418'900)